{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:51:16Z","timestamp":1767703876446,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.msard.2022.104422","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T18:40:08Z","timestamp":1668883208000},"page":"104422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial \u2013 The problem of generalizability"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-089X","authenticated-orcid":false,"given":"KO","family":"Jalusic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Ellenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104422_bib0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"year":"2010","series-title":"Fundamentals of Clinical Trials","author":"Friedman","key":"10.1016\/j.msard.2022.104422_bib0002"},{"key":"10.1016\/j.msard.2022.104422_bib0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2482-12-2","article-title":"To whom do the results of the multicenter, randomized, controlled INSECT trial (ISRCTN 24023541) apply? - assessment of external validity","volume":"12","author":"Fischer","year":"2012","journal-title":"BMC Surg."},{"key":"10.1016\/j.msard.2022.104422_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12764","article-title":"Clinical trial generalizability assessment in the big data era: a review","author":"He","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.msard.2022.104422_bib0005","unstructured":"European Medicines Agency - Committee for Medicinal Products for Human. Tysabri - Authorisation details, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tysabri (accessed 28. 06.)."},{"key":"10.1016\/j.msard.2022.104422_bib0006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis - success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.104422_bib0007","first-page":"9","article-title":"Safety of newer disease modifying therapies in multiple sclerosis","author":"Jalkh","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.msard.2022.104422_bib0008","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/NDT.S200930","article-title":"Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data","volume":"15","author":"Simbrich","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.msard.2022.104422_bib0009","unstructured":"European medicines agency - CHMP. Zinbryta: daclizumab."},{"year":"2018","series-title":"Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations For ZINBRYTA\u00ae (daclizumab) For Relapsing Multiple Sclerosis","author":"Biogen","key":"10.1016\/j.msard.2022.104422_bib0010"},{"key":"10.1016\/j.msard.2022.104422_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000204236","article-title":"Marrow suppression produced by repeated doses of cladribine","volume":"91","author":"Beutler","year":"1994","journal-title":"Acta Haematol."},{"key":"10.1016\/j.msard.2022.104422_bib0012","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104422_bib0013","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 6","key":"10.1016\/j.msard.2022.104422_bib0014","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00415-008-6019-5","article-title":"National MS registries","volume":"255","author":"Flachenecker","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104422_bib0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jclinepi.2011.06.017","article-title":"Monitoring drug safety with registries: useful components of postmarketing pharmacovigilance systems","volume":"65","author":"Willis","year":"2012","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2022.104422_bib0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40264-020-01007-1","article-title":"chances and challenges of registry-based pharmacovigilance in multiple sclerosis: lessons learnt from the implementation of the multicenter REGIMS Registry","volume":"44","author":"Simbrich","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.msard.2022.104422_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1352458520985118","article-title":"Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care","author":"Jalusic","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104422_bib0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104422_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101483","article-title":"Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors","volume":"38","author":"Sep\u00falveda","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104422_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101498","article-title":"Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation","volume":"38","author":"Mustonen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"year":"2021","series-title":"Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen","author":"Hemmer","key":"10.1016\/j.msard.2022.104422_bib0021"},{"key":"10.1016\/j.msard.2022.104422_bib0022","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.msard.2015.08.005","article-title":"Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database","volume":"4","author":"Capkun","year":"2015","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:56Z","timestamp":1761901556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":22,"alternative-id":["S2211034822009269"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104422","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial \u2013 The problem of generalizability","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104422"}}